GB1508925A - 1,5-inter-(2,5-thienylene)-2,3,4,17,18,19,20-heptanorprostaglandins - Google Patents

1,5-inter-(2,5-thienylene)-2,3,4,17,18,19,20-heptanorprostaglandins

Info

Publication number
GB1508925A
GB1508925A GB38949/76A GB3894976A GB1508925A GB 1508925 A GB1508925 A GB 1508925A GB 38949/76 A GB38949/76 A GB 38949/76A GB 3894976 A GB3894976 A GB 3894976A GB 1508925 A GB1508925 A GB 1508925A
Authority
GB
United Kingdom
Prior art keywords
prostaglandins
phenyl
alkyl
pharmaceutically acceptable
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB38949/76A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PFIZER
Pfizer Inc
Original Assignee
PFIZER
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PFIZER, Pfizer Inc filed Critical PFIZER
Publication of GB1508925A publication Critical patent/GB1508925A/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • C07D307/935—Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms
    • C07F9/655345—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a five-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
GB38949/76A 1975-09-29 1976-09-20 1,5-inter-(2,5-thienylene)-2,3,4,17,18,19,20-heptanorprostaglandins Expired GB1508925A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US05/617,481 US4065472A (en) 1975-09-29 1975-09-29 5-(2-Carboxythiophen-5-yl)-16-aryloxy-α-tetranor-ω-tetranorprostaglandins

Publications (1)

Publication Number Publication Date
GB1508925A true GB1508925A (en) 1978-04-26

Family

ID=24473823

Family Applications (1)

Application Number Title Priority Date Filing Date
GB38949/76A Expired GB1508925A (en) 1975-09-29 1976-09-20 1,5-inter-(2,5-thienylene)-2,3,4,17,18,19,20-heptanorprostaglandins

Country Status (11)

Country Link
US (1) US4065472A (cg-RX-API-DMAC7.html)
JP (1) JPS5242872A (cg-RX-API-DMAC7.html)
BE (1) BE846650A (cg-RX-API-DMAC7.html)
CA (1) CA1085832A (cg-RX-API-DMAC7.html)
DE (1) DE2640692C3 (cg-RX-API-DMAC7.html)
DK (1) DK435276A (cg-RX-API-DMAC7.html)
FR (1) FR2325371A1 (cg-RX-API-DMAC7.html)
GB (1) GB1508925A (cg-RX-API-DMAC7.html)
IE (1) IE44067B1 (cg-RX-API-DMAC7.html)
LU (1) LU75904A1 (cg-RX-API-DMAC7.html)
NL (1) NL7610761A (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL95952A0 (en) * 1989-10-19 1991-07-18 Sterling Drug Inc Aerosol composition for topical medicament
CA2705150C (en) * 2007-11-09 2016-06-14 Allergan, Inc. Substituted cyclopentanes having prostaglandin activity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1350971A (en) 1971-05-11 1974-04-24 Imp Chemi Als Ind Ltd Cyclopentane derivatives
US3922289A (en) * 1973-02-23 1975-11-25 Syntex Inc Trans-prostaglandin-like compounds and methods

Also Published As

Publication number Publication date
FR2325371A1 (fr) 1977-04-22
IE44067L (en) 1977-03-29
DK435276A (da) 1977-03-30
BE846650A (fr) 1977-03-28
US4065472A (en) 1977-12-27
LU75904A1 (cg-RX-API-DMAC7.html) 1977-05-11
IE44067B1 (en) 1981-08-12
DE2640692C3 (de) 1979-09-13
JPS5242872A (en) 1977-04-04
JPS5437136B2 (cg-RX-API-DMAC7.html) 1979-11-13
DE2640692B2 (cg-RX-API-DMAC7.html) 1979-01-18
DE2640692A1 (de) 1977-03-31
NL7610761A (nl) 1977-03-31
CA1085832A (en) 1980-09-16
FR2325371B1 (cg-RX-API-DMAC7.html) 1978-12-22

Similar Documents

Publication Publication Date Title
US4096179A (en) 13,14-Dihydro-16-phenoxy prostaglandin F1α analogs
GB1515414A (en) 2 descarboxy-2-(tetrazol-5-yl)-11-desoxy-15-substituted-omega-pentanorprostaglandins
US4127726A (en) Cis-13-PGE2, 15 methyl ethers
US4097508A (en) Cis-4,5-didehydro-13,14 dihydro-9, dioxy PGF compounds
US4119785A (en) 3,7-Inter-m-phenylene-4,5,6-trinor-12,13(E)-didehydro-13,14-dihydro-9-deoxy-PGD1 compounds
GB1386146A (en) Cyclopentane derivatives
US4068083A (en) 2,2-Difluoro-13,14-dihydro-PGE1 analogs
GB1396206A (en) Prostaglandins and the preparation thereof
US4124769A (en) 5-Oxa-13,14-didehydro-11-deoxy-PGF1 α compounds
US4065628A (en) 17-Phenyl-18,19,20-trinor-cis-4,5-didehydro-PGE, compounds
GB1508169A (en) Substituted cyclopenta(b)furan compounds useful in the synthesis of prostaglandin analogues
GB1479964A (en) 2,3-methylene prostaglandins and their preparation
GB1468830A (en) Cyclopentane derivatives
US4212987A (en) 2,2-Difluoro-PGE1 analogs
US4206311A (en) 2-Decarboxy-2-hydroxy-methyl-13,14-didehydro-17-phenyl PGF compounds
US4059614A (en) 2,2-Difluoro-16-phenoxy-PGE1 analogs
US4056555A (en) 2,2-Difluoro-16-phenoxy-PGA2 analogs
US4061866A (en) 2,2-Difluoro-13,14-dihydro-PGF1 analogs
US4212986A (en) 2,2-Difluoro-PGE2 analogs
US4041066A (en) 4,5-Cis-didehydro-PGE1 compounds
GB1495153A (en) Prostanoic acid derivatives
IE42966L (en) 8-azaprostaglandins and process for the preparation thereof.
US4140721A (en) 2-Decarboxy-2-hydroxymethyl-13,14-didehydro-17-phenyl-PGA, PGD and PGE compounds
US4010192A (en) 5-Oxa phenyl- and phenoxy-substituted prostaglandin E1 analogs
GB1392992A (en) Prostaglandin intermediates

Legal Events

Date Code Title Description
PS Patent sealed [section 19, patents act 1949]
PCNP Patent ceased through non-payment of renewal fee